Snapshot · Abbott Laboratories (ABT)

Data as of 2026-10-18T09:23:41.508Z

Fundamentals check

Market cap

$181.5B

P/E (TTM)

33.7

Gross margin

56.8%

Net margin

11.6%

ROE

10.5%

R&D / revenue

6.8%

Dividend yield

2.4%

FCF yield

4.8%

Latest dividend: $0.63/share (ex-date 2026-10-15, quarterly)

Summary

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

How it makes money

Revenue mix, latest fiscal year

• Medical Devices48.3%
• Diagnostic Products20.2%
• Nutritional Products19.1%
• Established Pharmaceutical Products12.5%

Recent Events

• 2026-10-16T10:20:56.000Zneutral

  Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

  可能与分析师对ABT季度其他关键指标的预期相关，尚未确定与实际业绩存在直接因果关系。

  Source: zacks.com

• 2026-10-15T05:23:13.000Zpositive

  Abbott Laboratories $ABT Stock: Krilogy Financial LLC Increases Stake

  可能与机构增持ABT相关，但不构成直接因果关系。

  Source: defenseworld.net

• 2026-10-15T05:23:13.000Zpositive

  Abbott (ABT) Stock: Krilogy Financial LLC Increases Stake

  可能与机构增持相关，但非直接因果。

  Source: defenseworld.net

• 2026-10-13T07:22:13.000Zneutral

  Abbott Laboratories ($ABT) Stock: Perpetual Ltd Trims Stake

  可能与机构交易活动相关，但不构成因果性声明。

  Source: defenseworld.net

• 2026-10-12T19:00:50.000Zpositive

  Abbott (ABT) Gains As Market Dips: What You Should Know

  或与市场波动相关，可能反映投资者情绪对ABT的影响。

  Source: zacks.com

• 2026-10-12T14:40:01.000Zneutral

  Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

  可能与投资者比较分析相关，未直接证明ABT优劣。

  Source: fool.com

• 2026-10-10T14:15:01.000Zpositive

  History Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.

  可能与长期展望相关，非对当前价格的直接因果解释。

  Source: fool.com

• 2026-10-07T09:00:00.000Zneutral

  Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

  可能与新品发布有关，未直接指向股价短期变动的因果关系。

  Source: prnewswire.com

• 2026-10-07T08:37:31.000Zpositive

  This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

  可能与分析师新覆盖及看涨观点相关，未必直接推动股价。

  Source: benzinga.com

• 2026-10-06T18:51:08.000Znegative

  Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

  可能与市场波动及情绪有关，非因ABT基本面恶化引发的必然结果。

  Source: zacks.com

Analyst view

Avg price target $123.67 from 6 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-09-02SellMCCOY JOHN A. JR.(officer: VICE PRESIDENT AND CONTROLLER)27 shares
• 2026-08-25SellFord Robert B(director, officer: CHAIRMAN AND CEO)180,297 shares
• 2026-08-25SellFord Robert B(director, officer: CHAIRMAN AND CEO)218,535 shares
• 2026-08-11SellMorrone Louis H.(officer: EXECUTIVE VICE PRESIDENT)5,850 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。